Oncothyreon Inc (ONTY) 1.21 $ONTY Oncothyreon Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncothyreon Inc (ONTY) 1.21 $ONTY

Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC)
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol "CASC," effective at market open on June 9, 2016.
CASC: 1.16 (+0.06), ONTY: 1.21 (+0.02)

Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 in HER2+ Metastatic Breast Cancer at ASCO
GlobeNewswire - Sun Jun 05, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of clinical data on its lead product candidate, ONT-380, at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO). ONT-380 is a highly selective small molecule HER2 inhibitor being developed in combination to treat HER2+ advanced or metastatic breast cancer.
ONTY: 1.21 (+0.02)

Oncothyreon reports 1Q loss
Automated Insights - Mon May 09, 3:19PM CDT
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Monday reported a loss of $12.9 million in its first quarter.
ONTY: 1.21 (+0.02)

Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update
GlobeNewswire - Mon May 09, 3:02PM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the quarter ended March 31, 2016.
ONTY: 1.21 (+0.02)

Oncothyreon (ONTY) Catches Eye: Stock Moves 11.6% Higher
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 3:31AM CDT
Oncothyreon Inc (ONTY) shares rose almost 12% in the last trading session.
ANIK: 51.31 (+1.39), ONTY: 1.21 (+0.02)

Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company, today announced the presentation of data highlighting the preclinical development of orally bioavailable, potent and selective checkpoint kinase 1 (Chk1) inhibitors. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
ONTY: 1.21 (+0.02)

Oncothyreon Appoints Scott D. Myers Chief Executive Officer
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Oncothyreon Inc. (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products to improve the lives and outcomes of patients with cancer, today announced the appointment of Scott D. Myers as President, Chief Executive Officer and a member of the Board of Directors, effective April 4, 2016.
ONTY: 1.21 (+0.02)

Three Stocks To Watch Friday Afternoon 3/18/2016
ACCESSWIRE - Fri Mar 18, 12:09PM CDT
MIAMI, FL / ACCESSWIRE / March 18, 2016 / Top Nasdaq Stocks is issuing a report on three stocks to watch. NWY, ONTY, and TBIO have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
TBIO: 0.38 (+0.01), NWY: 1.88 (+0.02), ONTY: 1.21 (+0.02)

Oncothyreon Reports Full Year and Fourth Quarter 2015 Financial Results & Provides Corporate Update
GlobeNewswire - Mon Mar 14, 6:17PM CDT
--Initiated Phase 2 ONT-380 Trial Based on Encouraging Combination Data--
ONTY: 1.21 (+0.02)

Endometrial Cancer - Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66589/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Endometrial Cancer Overview - Therapeutics Development - Pipeline Products for Endometrial Cancer - Overview - Pipeline Products for Endometrial Cancer - Comparative Analysis - Endometrial Cancer - Therapeutics under Development by Companies - Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes - Endometrial Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Endometrial Cancer - Products under Development by Companies - Endometrial Cancer - Products under Investigation by Universities/Institutes - Endometrial Cancer - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acceleron Pharma, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BeiGene(Beijing) Co.,Ltd - Boehringer Ingelheim GmbH - Cellceutix Corporation - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Pharmsynthez - Puma Biotechnology, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/s6...ndometrial
INCY: 91.02 (+0.81), IMGN: 2.87 (+0.09), ARQL: 1.70 (+0.04), LLY: 83.06 (+0.17), GSK: 45.01 (-0.06), ONTY: 1.21 (+0.02), MDVN: 64.13 (+0.14), MRK: 58.60 (-0.06), AZN: 33.89 (-0.25), AVEO: 1.00 (unch), GALE: 0.45 (+0.01), PBYI: 50.38 (+0.49), NVS: 82.97 (-0.29), KPTI: 7.50 (+0.12), XLRN: 34.38 (+0.46), EXEL: 9.17 (-0.01)

Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.
GlobeNewswire - Mon Jan 11, 7:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that Robert L. Kirkman, M.D., has retired as president and CEO and as a member of the Board of Directors, effective January 11, 2016. Oncothyreon's Board of Directors has appointed Christopher S. Henney, Ph.D., D.Sc., the company's chairman, to serve as interim CEO while the company conducts a comprehensive search for a new CEO.
ONTY: 1.21 (+0.02)

Is Oncothyreon (ONTY) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 7:31AM CST
Oncothyreon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ONTY: 1.21 (+0.02)

Where Investors Are Going - Complementary Research on Crocs, Oncothyreon, Nimble Storage and Rexnord
ACCESSWIRE - Mon Dec 21, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY), Nimble Storage Inc. (NYSE: NMBL) and Rexnord Corp. (NYSE: RXN). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 11.33 (unch), NMBL: 7.34 (-0.10), RXN: 21.20 (-0.09), ONTY: 1.21 (+0.02)

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
BusinessWire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 0.43 (-0.01), TSRO: 95.15 (+1.91), CTMX: 10.10 (+0.04), NK: 6.99 (+0.16), CNCR: 24.62 (+0.14), SRNE: 6.41 (+0.12), XNCR: 18.91 (-0.03), ONTY: 1.21 (+0.02), CYAD: 23.07 (-1.91)

4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Fri Dec 11, 8:51AM CST
NEW YORK, NY / ACCESSWIRE / December 11, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
EYES: 4.07 (+0.03), PBMD: 0.93 (unch), CGEN: 6.76 (+0.11), ONTY: 1.21 (+0.02)

Timing is Crucial, Upside Analysis - Analyst Reports on YRC Worldwide, Crocs, Oncothyreon and Nimble Storage
ACCESSWIRE - Thu Dec 10, 9:55AM CST
NEW YORK, NY / ACCESSWIRE / December 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: YRC Worldwide Inc. (NASDAQ: YRCW), Crocs Inc. (NASDAQ: CROX), Oncothyreon Inc. (NASDAQ: ONTY) and Nimble Storage Inc. (NYSE: NMBL). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CROX: 11.33 (unch), NMBL: 7.34 (-0.10), ONTY: 1.21 (+0.02), YRCW: 11.62 (-0.25)

Oncothyreon Inc (USA) Plunges on Confusing Data
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 09, 12:58PM CST
What: Oncothyreon   is down 30% at 1:30 p.m. EST after announcing updated data from its ongoing trials testing ONT-380 in patients with breast cancer yesterday. So what: From the stock move, you'd think the data was clearly negative, but it may...
ONTY: 1.21 (+0.02)

Global Brain Cancer Therapeutics Pipeline Review, H2 2015
M2 - Wed Dec 09, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wpxrw/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - AngioChem Inc. - Arrien Pharmaceuticals, LLC - BeiGene(Beijing) Co.,Ltd - Berg, LLC - biOasis Technologies Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals, LLC - Diffusion Pharmaceuticals LLC - e-Therapeutics Plc - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - MEI Pharma, Inc. - NatureWise Biotech & Medicals Corporation - Nektar Therapeutics - Nerviano Medical Sciences S.r.l. - Novartis AG - Novogen Limited - Oncology Research International Limited - Oncolytics Biotech Inc. - Oncothyreon Inc. - Pfizer Inc. - Philogen S.p.A. - Phosplatin Therapeutics LLC - Sanofi - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Takeda Pharmaceutical Company Limited - Tocagen Inc. - ViraTherapeutics GmbH - Zymeworks Inc. For more information visit http://www.researchandmarkets.com/research/2w...ain_cancer
ONCY: 0.33 (-0.02), PFE: 37.05 (+0.16), SPPI: 6.92 (+0.05), BMY: 75.41 (+0.60), STML: 7.35 (-0.05), ONTY: 1.21 (+0.02), NKTR: 17.48 (+0.19), MEIP: 1.46 (+0.10), ATNM: 1.78 (unch), ABBV: 66.54 (+0.31), EXEL: 9.17 (-0.01), NVS: 82.97 (-0.29)

Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
GlobeNewswire - Tue Dec 08, 3:05PM CST
Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
ONTY: 1.21 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 112

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 292

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 255

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Critical One Progresses on Acquisition of Howells Lake Project

Updated Category News Views 157

Critical One Energy Inc. Moves Forward with Howells Lake Acquisition Critical One Energy Inc. (formerly Madison Metals Inc.) has announced its latest strategic initiative: the acquisition of the Howells Lake Antimony Gold Project. This acquisition reflects the company's commitment to expanding its reach within the critical minerals sector, crucial for a sustainable...

Continue Reading
Breg, Inc. Welcomes Steve Ingel as New President Driving Growth

Updated Category News Views 467

Breg, Inc. Announces Promotion of Steve Ingel to President Breg, Inc., a prominent provider of orthopedic bracing and support solutions, has made a significant announcement regarding its leadership. Steve Ingel has been elevated to the role of President, effective immediately. This change reflects the company's strategy to enhance its growth trajectory and fortify its...

Continue Reading
Schwarzkopf® Wins 2025 Product of the Year for Excellence in Hair Care

Updated Category News Views 444

Schwarzkopf® Wins 2025 Product of the Year Award In an impressive recognition, Schwarzkopf® has won the 2025 Product of the Year USA Award for its innovative hair care line. The Schwarzkopf® Keratin Root Permanent Color and Keratin Root Temporary Color & Thickening Spray have emerged as champions in the Beauty category, voted for by 40,000 American shoppers. This...

Continue Reading
Symbotic Honored as a Top Innovator Workplace by Fast Company

Updated Category News Views 65

Symbotic Named to Fast Company’s Best Workplaces for Innovators Symbotic Inc. (Nasdaq: SYM), a pioneer in A.I.-enabled robotics for supply chains, has been ranked No. 58 on Fast Company’s sixth annual Best Workplaces for Innovators list. The honor celebrates organizations where new ideas are encouraged, supported, and moved into action—where innovation isn’t a...

Continue Reading
Growth Surge in Pharmaceutical Water Market to $89.9 Billion

Updated Category News Views 148

Pharmaceutical Water Market on the Rise The pharmaceutical water market is experiencing a robust increase, projected to surpass US$ 89.9 billion, driven by the escalating demand for high-purity water essential for drug manufacturing. Recent evaluations indicate that this sector, valued at approximately US$ 37.1 billion in the past years, is anticipated to expand at a...

Continue Reading